Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US

BACKGROUND: A significant minority of asthma patients remain uncontrolled despite the use of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA). A number of add-on therapies, including monoclonal antibodies (namely omalizumab) and more recently tiotropium bromide have been recommende...

Descripción completa

Detalles Bibliográficos
Autores principales: Zafari, Zafar, Sadatsafavi, Mohsen, Mark FitzGerald, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789632/
https://www.ncbi.nlm.nih.gov/pubmed/29422778
http://dx.doi.org/10.1186/s12962-018-0089-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789632/
https://www.ncbi.nlm.nih.gov/pubmed/29422778
http://dx.doi.org/10.1186/s12962-018-0089-8

Ejemplares similares